BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

The prevalence of food allergy is significantly lower in children with cystic fibrosis than in those without the condition in ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Premier research journal article provides validation for BiomX’s phage therapy platform, showcasing first-in-human Phase ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

ECMO use in cystic fibrosis with severe respiratory failure showed limited survival, highlighting the need for cautious ...

At 7 years old, Morgan Barrett was diagnosed with cystic fibrosis. Prior to her diagnosis, she struggled to gain weight ...

Most children with CF treated at a San Francisco CF clinic did not receive CF liver disease screening in accordance with current guidelines.

Affordable access to life-changing treatment for cystic fibrosis will be expanded to more Australians with a change to the Pharmaceutical Benefits Scheme.